Biogen Inc
NASDAQ:BIIB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
146.47
267.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biogen Inc
Operating Margin
Biogen Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 21.2B USD |
| Operating Margin |
26%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 310.3B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 141.6B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 115.3B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 102.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 134.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 77.3B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 35.7B EUR |
| Operating Margin |
-22%
|
Biogen Inc
Glance View
Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biogen Inc's most recent financial statements, the company has Operating Margin of 25.9%.
You don't have any saved screeners yet
